AZN — AstraZeneca PLC
Healthcare · ETF XLV · as of 2026-09-21
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
AstraZeneca PLC
NYQ
Healthcare · Drug Manufacturers - General
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Price & today
$168.10
ATR(14) 3.50 (2.08%)
| Stock today | +1.22% |
| Sector ETF today | +0.37% |
| Residual (stock-specific) | +0.85% |
Sector correlation
| 20-day correlation with XLV | 0.65 |
| 60-day correlation with XLV | 0.57 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $164.15 |
| 20 EMA | $163.57 |
| 50 EMA | $166.44 |
| EMA stack | NEUTRAL |
| RSI(14) | 58.1 |
| 52-week high distance | -20.97% |
| 52-week low distance | +15.29% |
Signals
| Market F&G | 45.6 |
| Bull% | 12.2% |
| OVTLYR status | SELL (48d) |
| Sector rank | #147 |
| Next earnings | 2026-10-30 (TNS, 39d) |
MarketSmith metrics - our compute
RS Rating
76.4
ADR%
1.7
RMV (tight)
20.0
Ext (ATR>20EMA)
1.3
Rel Vol
82.0%
U/D 50d
0.82
U/D 25d
1.16
Accum/Dist 25d
5 / 3
EPS YoY
+67.0%
LoD dist
28.0
Off 52w High
21.0%
Above 52w Low
15.3%
1W / 1M
+2.6 / +2.2
Avg $Vol 50d
581.4M
Mkt Cap (B)
260.7
Trend 8/8
no
Leads Group
YES
Sector XLV
+0.8% 1W
Base len (VCP)
19wk (7/9)
Coil (base shape)
85TVPX
not available: revenue(no EDGAR qtrs=1 fact)
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
25.2
Fwd P/E
14.5
PEG
1.4
Price/Book
5.0
Profit margin
17.0%
ROE
22.0%
Debt/Equity
64.2
Rev growth
+6.4%
Analyst target
$214 (+27%)
Analyst rating
STRONG_BUY
Institutional %
64.6%
Insider %
0.1%
Float %
96.0%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
24 / 146
Industry
Drug Manufacturers - General
Float
1.49B
Float turnover 20d
0.2%
Avg $Vol 20d / 50d
511.5M / 581.4M
Days to cover
1.0
Short % float
0.2%
Institutional %
64.6%
Weinstein stage
4
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Jul-24 | 0.99 | -8% | - | - |
| Nov-24 | 1.04 | +20% | - | - |
| Feb-25 | 1.05 | +44% | - | - |
| Apr-25 | 1.25 | +21% | - | - |
| Jul-25 | 0.79 | -20% | 14,457.0 | - |
| Nov-25 | 1.19 | +14% | 15,191.0 | - |
| Apr-26 | 1.29 | +3% | 15,288.0 | - |
| Jul-26 | 1.32 | +67% | 15,384.0 | +6% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 21 − Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note Zacks Investment Research
- Sep 21 − AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies Zacks Investment Research
- Sep 20 · Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook The Motley Fool
- Sep 20 · Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder The Motley Fool
- Sep 18 − Can AstraZeneca's Broad Pipeline Offset Recent Setbacks? Zacks Investment Research
- Sep 16 − Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views? Zacks Investment Research
- Sep 15 + Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics GlobeNewswire Inc.
- Sep 15 − New Strong Sell Stocks for September 15th Zacks Investment Research